Background: Artemisinin, a kind of sesquiterpene lactone endoperoxide, is isolated from Artemisia annua., has been used to effectively treat different forms of malaria. Recently, some researchers showed that artemisinin decreased serum triacylglycerol in rats. However, the molecular mechanism remains unclear. 
INTRODUCTION
With the increasing numbers of adults and children who are obese or overweight, non alcoholic fatty liver disease (NAFLD) is a highly prevalent chronic liver disease. 1, 2 It encompasses a wide spectrum of liver disorders and damages characterized by hepatic steatosis without significant alcohol consumption, including simple steatosis, inflammatory non-alcoholic steatohepatitis (NASH), liver cirrhosis and hepatocellular carcinoma. 3, 4 So far, the validated therapy of NAFLD remains uncertain. Traditional Chinese medicines have long been used to treat NAFLD with few adverse effects. 5 Artemisinin, or qinghaosu，a sesqui terpene lactone endoperoxide, is isolated from Artemisia annua. (sweet or annual wormwood) that has been used as a herbal remedy for fever and malaria. 6, 7 It is exciting that Tu Youyou was awarded half of the 2015 Submission Date: 27-12-2016; Revision Date: 24-01-2017; Accepted Date: 14-03-2017 Nobel Prize in Medicine because of her discovery concerning a novel therapy of artemisinin against malaria. Recently, arte misinin and its derivatives have been shown to induce growth arrest and apoptosis, 810 as well as inhibit angiogenesis by down regulation of the vascular endothelial growth factor and its cellular receptor KDR/ flk-1.
11,12 Furthermore, artemisinin inhibits rat cardiac hypertrophy, 13 prevents in vitro and in vivo invasion and metastasis of human hepatocellular carcinoma cells 14 and has function of anti-inflammatory and immu nomodulatory on contact hypersensitivity. 15 Aniefiok et al. (2010) found that artemisinin increased total serum cholesterol level, decreased serum triacylglycerol (TAG) level and reversed the ratio of Low Density Lipo protein to High Density Lipoprotein from 1:2 to 2:1 in rats. 16 However, its molecular mechanism involved in lipid metabolism is unclear. Although the pathogenesis of NAFLD is not completely understood, hepatic lipid metabolic disorders are likely to play important roles in its initiation and development. 17 Previous studies have shown that CD36, PPARα, and SREBP1 are important molecules in regulating fatty acid transport, lipolysis, and lipogenesis, respectively. They play important roles in hepatic and myocardial accumulation of triglyceride. 1822 Additionally, in vitro models of NAFLD have been constructed and used to study the hepatic lipid metabolic disorders in hepatic cells and screen drug candidates for suitability for the treatment of NAFLD. 23, 24 These models include hepato cyte cell lines and primary hepatocytes treated in culture with monounsaturated and saturated fatty acids, which simulate the key characteristics of NAFLD in human liver. 25, 26 Therefore, in order to understand the probable molecular mechanism of artemisinin involved in hepatic lipid metabolism, it is essential to investigate the effect of artemisinin on CD36, PPARα, and SREBP1 in the in vitro model. In the present study, we explored the alleviation of lipid accumulation effect of artemisinin on an in vitro model of NAFLD. Our results demonstrated that artemisinin attenuated lipid accumulation via the downregulation of CD36. It is expected that artemisinin may be a therapeutic candidate of the treatment of NAFLD in the near future.
MATERIALS AND METHODS

Antibodies and reagents
CD36, PPARα and SREBP1 rabbit polyclonal antibody were purchased from Santa Cruz Biotechnology Inc. (Texas, USA). β-actin rabbit monoclonal antibody was purchased from Cell Signaling Technology Inc. (MA, USA). The secondary antibody HRPlabeled Goat AntiRabbit IgG (H+L) was purchased from Novo protein Scientific Inc. (Shanghai, China). Reagents used in SDSpolyacrylamide gel electrophoresis were purchased from Shenghong Company (Shanghai, China). Other reagents used in our study were purchased from Solar bio life science (Beijing, China). Artemisinin (purity ≥ 98%) was purchased from Alexis Biochemistry (New York, USA). Its chemical structure was shown in Figure 1A .
Cell culture and Treatments
The human liver cancer SMMC7721 cell line was supplied by the Institute of Cell Biology (Shanghai, China). They were cultured at 37 ℃ under a humidified 5% CO 2 atmosphere in RPMI1640 medium (GIBCO/ Invitrogen, Camarillo, CA, USA) supplemented with 10% fetal bovine serume (Biological Industry, Kibbutz Beit Haemek, Israel) and 1% penicillin-streptomycin (10,000 U/ml penicillin and 10 mg/ml streptomycin, Solarbio life science, Beijing, China). Other reagents used in our study were purchased from Solarbio life science Co., Ltd (Beijing, China) and Aladdin Industrial Corporation (Los Angeles, USA). Artemisinin was dissolved in dimethylsulfoxide (DMSO) to a concentration of 200 μM (final concentration of DMSO was less than 0.1% by volume) and was added at the indicated concentrations in SMMC7721 cells.
Cell viability assay
Cell viability was evaluated by Cell Counting Kit8 (Dojindo, Tokyo, Japan) according to the manufacturer's instruction. Cells were plated in 96well microwell plate in 0.1 ml volume of RPMI1640 medium with 10% FBS, at a density of 0.1×10 5 cells/well. Absorbance was measured at 450 nm with an iMark Microplate reader (BioRad, California, USA).
Oil Red O staining
The SMMC7721 cells at 0.5×10 5 cells/well were seeded in 48well plates and preincubated with RMPI 1640 containing 10% of FBS for 12 h. The cells were then exposed to different concentration of artemisinin for 12 h and then treated with 0.5 mM or 1.0 mM oleic acid (OA) for 24 h or 48 h, fixed with 4% paraformal dehyde and stained with a freshly prepared working solution of Oil Red O (three parts of 1% stock in iso propanol and two parts double distilled H 2 O) for 30 min at room temperature. The stained cells were observed under a fluorescence microscope (Olympus BX51, Tokyo, Japan). To quantify the Oil Red O content, isopropanol was added to each sample, which was shaken at room temperature for 5 min, and the optical density of each 100 μl isopropanol extracted sample was read with a spectrophotometer (Bio Tek Synergy2, Vermont, American) at 510 nm.
Measurement of cellular triglyceride concentration in SMMC-7721 cells
The concentration of triglyceride (TAG) in cells was measured with enzymatic assays from Nanjing Jiangcheng Bioengineering Institute (Nanjing, China), according to the manufacturer's instructions. Absorbance was measured with a microplate spectrophotometric system at 546 nm. The result of TAG was expressed as mmol TAG per g protein (mmol/g protein).
Reverse Transcription-Polymerase Chain Reaction and real time PCR
The expression of CD36, PPARα and SREBP1 mRNA in the cells was determined by Reverse Transcription Polymerase Chain Reaction (RTPCR) and real time PCR. The cells (5×10 5 cells/well) in 6well plates were pretreated with artemisinin at indicated concentration for 12 h and then treated with 1.0 mM OA for 24 h. Total RNA was prepared from cells using cold Trizol (Takara, Japan) according to the manufacturer's proto col. The cDNA was synthesized by reverse transcription with PrimeScrtipt RT regent kits (Takara, Japan) according to the manufacturer's protocol and then subjected to PCR and realtime PCR detection with Emerald Amp PCR Master Mix and SYBR Premix Ex Taq (Tli RNAaseH Plus) kit (Takara, Japan). The primer sequences were as follows: 5'-GAGAACTGT TATGGGGCTAT-3' (sense), 5'-TTCAACTGGAGA GGCAAAGG-3' (antisense) for CD36, 5'-GCGATCTA GAGAGCCC GTTATC-3' (sense), 5'-GCCAAAGCTT CCAGAACTATCC-3' (antisense) for PPARα, 5'-CT GGTCGTAGATGCGGAGAA-3' (sense), 5'-CATT GATGGAGGAGCGGTAG-3' (anti-sense) for SREBP1 and 5'-CGGCTACCACATCCAAGGAAG-3' (sense), 5'-AGCTGGAATTACCG CGGCT-3' (antisense) for 18s RNA.
Western Blotting
The cell pellets were collected by centrifugation and washed two times with cold PBS, then dissolved in lysis buffer and lysis for 30 min. Insoluble materials were removed by centrifugation, the supernatant was saved and protein content was determined by the Bradford method (Bradford, 1976). Protein (50-80 μg) were sepa rated on 8% SDSPAGE (laemmli, 1970) and transferred to Amersham Hybond-P polyvinyliden fluoride(PVDF) membrans (GE healthcare, Buckinghamshire, UK) and probed with specific primary antibodies and then with secondary antibody. Proteins were detected using a chemiluminescense-based kit (Tian Gen Biotech Co., Ltd, China). Signal density was detected using the MFChemi BIS Family including gel capture software (DNR Bio-Image system, Ltd., Jerusalem, Israel) and quantitatively analyzed by densitometry using the Image J software.
Statistical Analysis
Values were expressed as means ± standard deviations. Statistical analysis was performed using the Student's ttest. Values of p<0.05 were considered to be statistically signinficant.
RESULTS
Cytotoxic effect of artemisinin and OA on SMMC-7721 cells
Using the WST8 based Colorimetric Assay Cell Counting kit 8, the cytotoxicity of OA and artemisinin on SMMC-7721 cells was measured. After treatment for 24, 48 and 72 h, 0.5 mM and 1.0 mM OA had no obvious effect on the viability of SMMC7721 cells, however 1.5 mM and 2.0 mM OA caused 10% and 81% cell death compared with control separately after treating for 24 h (Fig.1 B) . At 24 h and 48 h, 50 μM and 100 μM artemisinin had no effect on cell viability of SMMC7721 cells. However, when treated cells with 100 μM artemisinin for 72 h, 17% cells were dead and treatment of 200 μM artemis inin caused more than 50% cells death (Figure 1 C) .
Construction an in vitro model of NAFLD by OA
To establish an in vitro cellular model of NAFLD, SMMC7721 cells were treated with different concen trations of OA. As shown in Figure 2A , 0.5 mM and 1.0 mM OA increased numbers of lipid droplets compared with control cells and 1.0 mM OA caused more lipid droplets than 0.5 mM OA. Furthermore, as shown in Figure 2B , lipid content was significantly elevated in a concentrationdependent manner. After treated for 24 h and 48 h, the lipid content in cells treated with 1.0 mM OA was 1.7 and 1.4 times than those treated with 0.5 mM OA. According to these data, we chose 1.0 mM OA to construct the in vitro model of NAFLD.
Artemisinin reduced intracellular lipid accumulation and TAG concentration in SMMC-7721 cells induced by OA
Next, 50 μM and 100 μM artemisinin was chosen to treat model cells of NAFLD. As shown in Figure 3A , there was significant difference between cells treated with or without 100 μM artemisinin. The numbers and sizes of the lipid droplets were significantly reduced after the treatment of 100 μM artemisinin with the observation of fluorescence microscope and 50 μM artemisinin had no effect. Furthermore, lipid content was significantly elevated after treated with 1.0 mM OA for 24 h, com pared with the control cells (p<0.01), while 100 μM artemisinin decreased lipid content induced by 1.0 mM OA (p<0.05) in SMMC7721 cells ( Figure 3B ). Com pared to 0.272 mmol/g protein in the control group, the intracellular TAG content increased significantly in the OA treated cells and reached 0.596 mmol/g protein (p<0.01 versus the control), and decreased significantly after treated with 100 μM artemisinin and it was 0.378 mmol/g protein (p<0.01 versus the OA treated cells) ( Figure 3C ). The results showed that artemisinin reduced intracellular lipid accumulation and TAG concentration in the cellular model of NAFLD.
Effects of artemisinin on expression of lipogenic and lipolytic genes in SMMC-7721 cells
The mRNA levels of CD36, PPARα, SREBP1 in different treated cells were detected by RTPCR and realtime PCR, respectively. The results were shown in Figure 4 , the mRNA expression of CD36 was significantly upregulated about 2fold in the OA group compared with that in the control group (p<0.01). However, the upregulated effect of OA was decreased to 0.23 fold of control group by 100 μM artemisinin (p<0.01). The mRNA of SREBP1 was both decreased in OA and OA with artemisinin groups compared with control group (p<0.01), however artemisinin had no effect on mRNA expression of SREBP1compared to OA group. In con trast, the mRNA expression of PPARα had no change in both OA and OA with artemisinin groups and arte misinin had no effect on it.
The proteins of CD36, PPARα, SREBP1 were detected by western blot, respectively. The results were presented in Figure 5 . The level of CD36 in OA group was elevated and decreased by artemisinin, similar as the result of mRNA expression. PPARα and SREBP1 protein levels were different from their mRNA expressions, which were upregulated by OA while artemisinin did not change their high levels.
DISCUSSION
According to our previous studies, OA was chosen to treat SMMC7721 cells to establish an in vitro model of NAFLD. 27, 28 The present results showed that intracel lular lipid droplets increased significantly in the OAtreated cells, indicating that the in vitro NAFLD model had been successfully established. In this cellular model, we observed that intracellular lipid accumulation and TAG concentration were significantly reduced by 100 μM artemisinin. Additionally, artemisinin was found to downregulate both mRNA and protein expressions of CD36 and have no effect on those of PPARα and SREBP1. As very important molecules in regulating lipid metabo lism, PPARα is a nuclear receptor expressed primarily in the liver and regulates the transcription of genes involved in hepatic fatty acid uptake and oxidation.
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While SREBP1 is the most important transcription factor regulation gene involved in de novo lipogenesis. 31 From our results, it suggests that artemisinin had no impact on hepatocellular lipid synthesis and fatty acid oxidation. CD36/FAT resides in the plasma membrane of hepato cytes and is known to translocate to the outer mitochon drial membrane to facilitate uptake and transport of fatty acids across the mitochondrial membrane. 32 Previ ously, Koonen et al. found that highfat diet increased expression of hepatic CD36 protein and hepatic tri glyceride storage. 18 In CD36 knockout mice, uptake and utilization of long chain fatty acids in muscle and adipose tissues was reduced. 33 Krammer et al. once reported that overexpression of CD36 in Huh 7 and HepG2 cells increased uptake of OA. 34 Podszun et al. indicated that orally administered atorvastatin and RRR α-tocopherol (αT) individually, but not synergistically, prevent dietinduced lipid accumulation in the liver of guinea pigs by downregulation of hepatic CD36 protein. 35 In our work, it showed that OA induced upregulation of CD36 and increase of TAG, while arte misinin reduced the expression of CD36 and lipid accu mulation. It suggests that artemisinin reduced hepatic lipid accumulation via downregulation of CD36 protein.
For another, Puthanveetila et al. indicated that excess lipid induce cardiac triglyceride accumulation through activation of a FoxO1-iNOS-CD36 pathway. 36 Wang et al. demonstrated that rapamycin inhibits hepatic CD36 translational efficiency through the mTOR path way, resulting in reduction of CD36 protein expression and alleviation of hepatic steatosis. 37 Future studies are required to explore the molecular mechanism of artermisinin involved in lipid metabolism via inhibition of CD36 protein.
CONCLUSION
In conclusion, we demonstrated that artemisinin atten uated lipid accumulation via the downregulation of CD36 in the cellular model of NAFLD (Figure 6 ). The results obtained here suggest that artemisinin may be a therapeutic candidate of the treatment of NAFLD in the near future. 
